臓器チップのスタートアップ久浪智医、2億台湾ドルのシリーズA調達
Meet創業小聚 · 2026-10-19
2024年創業の久浪智医（Anivance AI）は、AIと臓器チップで創薬検証を加速する。2億台湾ドル（約600万米ドル）のシリーズAを完了し、既存投資家が全員参加した。資金は実験設備の拡充と海外展開に充てる。吸入型肺チップは米FNIHの試験計画に採択され、顧客は30社超、米国子会社も設立済み。
Organ-on-chip startup Anivance AI closes NT$200 million Series A with all existing investors following on
Anivance AI, founded in 2024 to speed drug testing with AI and organ-on-chip models, has raised a NT$200 million (about US$6 million) Series A in which every existing investor took part. Funds go to lab infrastructure and overseas expansion; its inhalation lung-chip was picked for a US FNIH pilot, and it has over 30 clients and a US subsidiary.